Comparison
CagriSema vs. Pramlintid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
151126-32-8
Molecular weight
no data
3949.4 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
0
of which in humans
1
0
Effects recorded
2
2
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between CagriSema and Pramlintid?
- CagriSema is classified as "Metabolic", while Pramlintid is classified as "Metabolic". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Pramlintid?
- The highest available evidence level is "Human RCT" for CagriSema and "Human RCT" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Pramlintid in Germany and the United States?
- Germany: CagriSema — Unapproved, Pramlintid — Unapproved. United States: CagriSema — Unapproved, Pramlintid — Prescription. These are factual summaries with source and review date on the individual pages.